The most talked about and market-moving research requests around Wall Street are now in one place. Here are today’s research calls that investors should know, as compiled by Fly.
Top 5 improvements:
-
HSBC is upgraded Nio (NIO) Buy from Hold with a $6.80 price target, up from $4.80. The company has a positive outlook and has “strong confidence” in Nio’s 2026 volume growth and revenue improvement trajectory after the Q4 report.
-
Wells Fargo is up Ollie’s Bargain Store (OLLI) from equal weight to overweight with a $130 price target, up from $120. The company is encouraged by the Q4 update and believes that Oli’s “story continues to build momentum.”
-
Wells Fargo is up nutrients (NTR) from equal weight to overweight with a $100 price target, up from $77. The company sees price hikes across “several chemical chains” due to the conflict in Iran. Wells Air Products (APD) and Celanese also upgraded to overweight.
-
JPMorgan rose alco (AA) from Underweight to Neutral with a price target of $68, up from $50. Since the conflict in Iran began, aluminum prices have risen 12% on regional supply risks, the company said in a research note to investors.
-
Barclays has risen Murphy’s Fat (MUR) from underweight to equal weight with a price target of $33, up from $29. The company has raised its 2026 oil price estimates due to the Iran conflict and believes cash flow for the exploration and production group is understated.
Top 5 lowest ratings:
-
Barclays downgraded Adobe ( ADBE ) from overweight to equal weight with a price target of $275, down from $335. The biggest news of the quarter, the company says, is that longtime Adobe CEO Shantanu Narine is transitioning.
-
The citizens went down Ever Commerce (EVCM) to outperform the market without a price target. The company appears mixed in its Q4 report with payments revenue declining in the first year since EverCommerce went public in July 2021.
-
Morgan Stanley downgraded NerdWallet (NRDS) from equal weight to underweight with a $9 price target, down from $14. The company considers the consensus earnings estimate for the company to be too high.
-
William Blair went down PagerDuty (PD) Outperform the market without a price target. The company reported “disappointing” Q4 results, with annual recurring revenue growth of just $2M and 1% year-over-year, the company told investors in a research note.
-
Baird went down immutep ( IMMP ) from Outperform to Neutral with a $1 price target, down from $7. An independent data monitoring committee recommended stopping the company’s original TACTI-004 study in non-small cell lung cancer following a planned futility analysis, the company said in a research note to investors.
